الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 154 |  |  |
| | | from | 154 | | |
Abstract
Quinazoline derivatives constitute an important class of heterocyclic compounds, many of them possessed a wide range of biological activities as anti- inflammatory, analgesic, antifungal, antibacterial, anticancer and anticonvulsant activities.
The presence of natural bioactive products of quinazolines encourage researchers to take quinazoline nucleus as a core for the synthesis of multitude derivatives.
Looking at the biological significance of quinazoline nucleus, we aimed to design and synthesize new quinazoline derivatives and screen them for their cytotoxic activity. Moreover, other quinazolines and substituted quinazolinone derivatives are hybridized with different moieties in order to produce compounds with synergistic antitumor activity.
On the light of these findings, a new series of 2-substituted quinazolinone, 2,3-disubstituted quinazolinones and 2,4-disubstituted quinazoline derivatives were prepared.
This thesis consists of the following parts:
1. Introduction:
In this section, literature review presents the various biological and pharmacological activities of quinazolines with a focus on their anticancer activities. Moreover, it displays different methods for their preparation.
2. Aim of the work:
It includes the rationale upon which the newly synthesized compounds were designed.
3. Discussion:
It deals with the discussion of the various experimental methods, mechanisms and conditions of reactions adopted for the synthesis of the prepared compounds and the confirmation of their structures by brief data of infrared, mass, 1H-NMR and 13C-NMR spectra.
4. Experimental:
This part presents the practical procedures used for the synthesis of reported and new intermediates, as well as new final compounds. Also, it includes their microanalytical, physical and spectral data.
In order to obtain the new compounds, the following were prepared:
Reported intermediates (7 compounds):
• 2-Methylquinazolin-4(3H)-one II.
• 4-Chloro-2-methylquinazoline III.
• 2-(Bromomethyl)quinazolin-4(3H)-one VI.
• Methyl 2-acetamidobenzoate XIII.
• 2-(2-Methyl-4-oxoquinazolin-3(4H)-yl)acetic acid XIV.
• 2-(2-Methyl-4-oxoquinazolin-3(4H)-yl)acetyl chloride XV.
• 2-(2-Methyl-4-oxoquinazolin-3(4H)-yl)acetohydrazide XVI.
New intermediates (3 compounds):
• 4-((4-Chloroquinazolin-2-yl)methylamino)benzenesulfonamide VIII.
• N’-(2-(Bromomethyl)quinazolin-4-yl)benzohydrazide XI.
• N’-Formyl-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)acetohydrazide XX.
New final compounds (25 compounds):
• 2-((2-Methylquinazolin-4-yl)amino)propanoic acid IVa.
• 2-((2-Methylquinazolin-4-yl)amino)succinic acid IVb.
• 2-((2-Methylquinazolin-4-yl)amino)pentanedioic acid IVc.
• 2-((2-Methylquinazolin-4-yl)amino)-3-phenylpropanoic acid IVd.
• 3,5-Dimethoxy-N’-(2-methylquinazolin-4-yl)benzohydrazide Va.
• 3,4,5-Trimethoxy-N’-(2-methylquinazolin-4-yl)benzohydrazide Vb.
• N’-(2-Methylquinazolin-4-yl)benzohydrazide Vc.
• 4-((4-Oxo-3,4-dihydroquinazolin-2-yl)methylamino)benzenesulfonamide
VIIa.
• N-(4-((4-Oxo-3,4-dihydroquinazolin-2- yl)methylamino)phenylsulfonyl)acetamide VIIb.
• 1-(4-((4-Oxo-3,4-dihydroquinazolin-2- yl)methylamino)phenylsulfonyl)guanidine VIIc.
• N-(Isoxazol-3-yl)-4-((4-oxo-3,4-dihydroquinazolin-2- yl)methylamino)benzenesulfonamide VIId.
• 4-((4-Oxo-3,4-dihydroquinazolin-2-yl)methylamino)-N-(pyrimidin-2- yl)benzenesulfonamide VIIe.
• N-(4,6-Dimethylpyrimidin-2-yl)-4-((4-oxo-3,4-dihydroquinazolin-2- yl)methylamino)benzenesulfonamide VIIf.
• 2-((2-(((4-Sulfamoylphenyl)amino)methyl)quinazolin-4-yl)amino)propanoic acid IXa.
• 2-((2-(((4-Sulfamoylphenyl)amino)methyl)quinazolin-4-yl)amino)succinic acid IXb.
• 2-((2-(((4-Sulfamoylphenyl)amino)methyl)quinazolin-4- yl)amino)pentanedioic acid IXc.
• 3-Phenyl-2-((2-(((4-sulfamoylphenyl)amino)methyl)quinazolin-4- yl)amino)propanoic acid IXd.
• 4-((4-(2-Isonicotinoylhydrazinyl)quinazolin-2- yl)methylamino)benzenesulfonamide Xa.
• 4-((4-(2-Benzoylhydrazinyl)quinazolin-2- yl)methylamino)benzenesulfonamide Xb.
• 4-((4-(2-(3,5-Dimethoxybenzoyl)hydrazinyl)quinazolin-2- yl)methylamino)benzenesulfonamide Xc.
• 4-((4-(2-(3,4,5-Trimethoxybenzoyl)hydrazinyl)quinazolin-2- yl)methylamino)benzenesulfonamide Xd.
• 1-(2-(2-Methyl-4-oxoquinazolin-3(4H)-yl)acetyl)pyrazolidine-3,5-dione
XVII.
• 3-(2-(3,5-Dimethyl-1H-pyrazol-1-yl)-2-oxoethyl)-2-methylquinazolin- 4(3H)-one XVIII.
• 2-Methyl-3-(2-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-2- oxoethyl)quinazolin-4(3H)-one XIX.
• 3-((1,3,4-Oxadiazol-2-yl)methyl)-2-methylquinazolin-4(3H)-one XXI.
5. Pharmacological Screening: Antitumor Screening:
Fourteen compounds were chosen by U. S. National Cancer Institute for antitumor screening. The results revealed that all tested compounds showed moderate activity against panel of cell line especially CNS and renal cancer, while five compounds Vb, VIIb, IXd, XIX and XXI displayed a significant activity against one cell line.
6. References:
This part includes 148 references ranging from 1887 to 2015.
7. Arabic Summary.